is a neuropeptide developed by the Institute of Molecular
Genetics; Russian Academy of Sciences, Moscow, Russia and
“Lomonosov” University, Moscow . Research started
in 1982 and involved over 30 scientists in the fields of
Neurochemistry, Neurobiology, Neurology and Biochemistry
from the Russian Federation.
focus was on a short fragment of ACTH, Pro8-Gly9-Pro10 ACTH(4-10)
and by dissociation of the combination of amino acids, substitution
and special linkages a peptide was synthesized which had unique
Extensive testing over a period of 14 years resulted in the
approval of the Russian Federation Ministry of Public Health
and Pharmaceutical Industry on 28 March, 1996, for the clinical
use of SEMAX® in the Russian Federation
as a neuroactive peptide with endogenous regulatory properties
affecting cerebral cellular processes which are beneficial
in protecting and enhancing the recovery of cerebral functions
after ischemic insults like : brain stroke, closed head injuries.
Neurodegenerative processes like in Alzheimer’s disease,
Parkinson’s disease and Huntington’s Chorea.
also influences the intellectual capacities and memory as
well as concentration of normal, healthy persons subjected
to stressful working conditions, increasing their mental capacities
and diminishing the index of workload.